460
Participants
Start Date
December 18, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
HS-20089
All patients will receive intravenous HS-20089 once every three weeks (Q3W) until experiencing objective disease progression (except for study drug treatment beyond progression) or meeting other protocol-specified criteria of study treatment discontinuation.
RECRUITING
Lingying Wu, Beijing
RECRUITING
Anhui Provincial Cancer Hospital, Hefei
RECRUITING
Peking University Cancer Hospital, Beijing
SUSPENDED
Chongqing University cancer Hospital, Chongqing
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Sun Yat-Sen Memorial Hospital Sun Yat-Sen University, Guangzhou
RECRUITING
Guangxi Cancer Hospital, Nanning
RECRUITING
Hainan General Hospital, Haikou
RECRUITING
The fourth Hospital of Heibei Medical University, Shijiazhuang
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Hubei Cancer University, Wuhan
RECRUITING
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
RECRUITING
Hunan Cancer Hosipital, Changsha
RECRUITING
Xiangya Hospital of Central South University, Changsha
RECRUITING
Nanjing Drum Tower Hospital, Nanjing
RECRUITING
Jilin Cancer Hospital, Changchun
SUSPENDED
The Second Hospital of Dalian Medical University, Dalian
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
RECRUITING
Cancer Hospital of Shandong First Medical University, Jinan
RECRUITING
Obstetrics & Gynecology Hospital of Fudan University, Shanghai
RECRUITING
Shanxi Cancer Hospital, Taiyuan
RECRUITING
The first Affiliated Hospital of Xi'an Jiaotong University, Xi’an
RECRUITING
Tianjin Medical University cancer institute & Hospital, Tianjin
RECRUITING
Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang
RECRUITING
Yunnan Cancer Hospital, Kunming
RECRUITING
Zhejiang Cancer Hospital, Hanzhou
Hansoh BioMedical R&D Company
INDUSTRY